Promising Trial Results and Pipeline Expansion Justify Buy Rating for Iovance Biotherapeutics
Yanan Zhu, an analyst from Wells Fargo, maintained the Buy rating on Iovance Biotherapeutics (IOVA – Research Report). The associated ...
Arcellx Inc’s Anito-cel: Promising Efficacy and Best-in-Class Safety Profile Justify Buy Rating
Analyst John Newman from Canaccord Genuity maintained a Buy rating on Arcellx Inc (ACLX – Research Report) and keeping the price target ...